Evoke Pharma Inc. (NASDAQ:EVOK) was down 3.2% during mid-day trading on Monday . The stock traded as low as $2.43 and last traded at $2.45, with a volume of 891,599 shares traded. The stock had previously closed at $2.53.

Several equities research analysts have recently issued reports on EVOK shares. Rodman & Renshaw reissued a “buy” rating and set a $27.00 price objective on shares of Evoke Pharma in a research report on Monday, July 11th. Noble Financial downgraded shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, July 19th. FBR & Co reissued an “outperform” rating and set a $9.00 price objective on shares of Evoke Pharma in a research report on Sunday, July 31st. Brean Capital reissued a “buy” rating on shares of Evoke Pharma in a research report on Friday, July 8th. Finally, Northland Securities downgraded shares of Evoke Pharma from an “outperform” rating to a “market perform” rating in a research report on Monday, July 18th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company’s stock. Evoke Pharma has an average rating of “Hold” and a consensus price target of $13.34.

The company’s 50 day moving average price is $5.27 and its 200 day moving average price is $4.73. The stock’s market capitalization is $17.74 million.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.04. On average, equities analysts expect that Evoke Pharma Inc. will post ($1.43) EPS for the current year.

In other news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $4.70, for a total value of $1,617,364.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.